05:16 PM EDT, 03/20/2025 (MT Newswires) -- Allurion Technologies ( ALUR/WS ) said Thursday that initial trial results from the Allurion ( ALUR/WS ) balloon in combination with semaglutide showed total body weight loss and lean body mass gains.

The company treated 52 patients in the study and the average total body weight loss was 20.3% after eight months while the lean body mass increased by 15%, according to the company.

Shares of the company were up 29% in recent after-hours activity.